Click-based synthesis of triazolobithiazole ΔF508-CFTR correctors for cystic fibrosis

被引：16
作者：
Donald, Michael B. [3 ]
Rodriguez, Kevin X. [3 ]
Shay, Hannah [3 ]
Phuan, Puay-Wah [1 ,2 ]
Verkman, A. S. [1 ,2 ]
Kurth, Mark J. [1 ,2 ]
机构：
[1] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA
[3] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2012年 / 20卷 / 17期
基金：
美国国家科学基金会; 美国国家卫生研究院;
关键词：
CuAAC; Triazolobithiazole; Cystic fibrosis; CF corrector; TRANSMEMBRANE CONDUCTANCE REGULATOR;
D O I：
10.1016/j.bmc.2012.06.046
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Copper catalyzed azide-alkyne cycloaddition (CuAAC) chemistry is reported for the construction of previously unknown 5-(1H-1,2,3-triazol-1-yl)-4,5'-bithiazoles from 2-bromo-1-(thiazol-5-yl)ethanones. These novel triazolobithiazoles are shown to have cystic fibrosis (CF) corrector activity and, compared to the benchmark bithiazole CF corrector corr-4a, improved log P values (4.5 vs 5.96). (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5247 / 5253
页数：7
相关论文
共 50 条
  • [31] Mechanism-based corrector combination restores ΔF508-CFTR folding and function
    Okiyoneda, Tsukasa
    Veit, Guido
    Dekkers, Johanna F.
    Bagdany, Miklos
    Soya, Naoto
    Xu, Haijin
    Roldan, Ariel
    Verkman, Alan S.
    Kurth, Mark
    Simon, Agnes
    Hegedus, Tamas
    Beekman, Jeffrey M.
    Lukacs, Gergely L.
    NATURE CHEMICAL BIOLOGY, 2013, 9 (07) : 444 - U69
  • [32] In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing Delta F508-CFTR
    Rubenstein, RC
    Egan, ME
    Zeitlin, PL
    JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (10) : 2457 - 2465
  • [33] Functional rescue of F508del-CFTR using small molecule correctors
    Molinski, Steven
    Eckford, Paul D. W.
    Pasyk, Stan
    Ahmadi, Saumel
    Chin, Stephanie
    Bear, Christine E.
    FRONTIERS IN PHARMACOLOGY, 2012, 3
  • [34] Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
    Donaldson, Scott H.
    Pilewski, Joseph M.
    Griese, Matthias
    Cooke, Jon
    Viswanathan, Lakshmi
    Tullis, Elizabeth
    Davies, Jane C.
    Lekstrom-Himes, Julie A.
    Wang, Linda T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (02) : 214 - 224
  • [35] Rescue of dysfunctional ΔF508-CFTR chloride channel activity by IBMX
    Schultz, BD
    Frizzell, RA
    Bridges, RJ
    JOURNAL OF MEMBRANE BIOLOGY, 1999, 170 (01) : 51 - 66
  • [36] Cross-linking of ΔF508-CFTR promotes its trafficking to the plasma membrane
    Bernard, Karen
    Kirk, Kevin L.
    CHANNELS, 2010, 4 (04) : 251 - 254
  • [37] Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
    Hanrahan, John W.
    Sato, Yukiko
    Carlile, Graeme W.
    Jansen, Gregor
    Young, Jason C.
    Thomas, David Y.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (08) : 711 - 724
  • [38] Genistein potentiates wild-type and Delta F508-CFTR channel activity
    Hwang, TC
    Wang, F
    Yang, ICH
    Reenstra, WW
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1997, 273 (03): : C988 - C998
  • [39] Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
    Cholon, Deborah M.
    Quinney, Nancy L.
    Fulcher, M. Leslie
    Esther, Charles R., Jr.
    Das, Jhuma
    Dokholyan, Nikolay V.
    Randell, Scott H.
    Boucher, Richard C.
    Gentzsch, Martina
    SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (246)
  • [40] Manipulating proteostasis to repair the F508del-CFTR defect in cystic fibrosis
    Speranza Esposito
    Antonella Tosco
    Valeria R. Villella
    Valeria Raia
    Guido Kroemer
    Luigi Maiuri
    Molecular and Cellular Pediatrics, 3 (1)
12345